Exelixis (EXEL) Revenue & Revenue Breakdown
Exelixis Revenue Highlights
Latest Revenue (Y)
$1.83B
Latest Revenue (Q)
$637.18M
Main Segment (Y)
Product, Gross
Main Geography (Y)
UNITED STATES
Exelixis Revenue by Period
Exelixis Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-29 | $1.83B | 13.60% |
| 2022-12-30 | $1.61B | 12.27% |
| 2021-12-31 | $1.43B | 45.31% |
| 2021-01-01 | $987.54M | 2.04% |
| 2020-01-03 | $967.77M | 13.35% |
| 2018-12-28 | $853.83M | 88.70% |
| 2017-12-29 | $452.48M | 136.34% |
| 2016-12-30 | $191.45M | 415.05% |
| 2016-01-01 | $37.17M | 48.03% |
| 2014-12-31 | $25.11M | -19.87% |
| 2013-12-31 | $31.34M | -33.96% |
| 2012-12-28 | $47.45M | -83.62% |
| 2011-12-30 | $289.64M | 56.52% |
| 2010-12-31 | $185.04M | 21.93% |
| 2010-01-01 | $151.76M | 28.76% |
| 2009-01-02 | $117.86M | 3.87% |
| 2007-12-28 | $113.47M | 15.00% |
| 2006-12-29 | $98.67M | 29.90% |
| 2005-12-31 | $75.96M | 43.71% |
| 2004-12-31 | $52.86M | 2.56% |
| 2003-12-31 | $51.54M | 16.29% |
| 2002-12-31 | $44.32M | 8.09% |
| 2001-12-31 | $41.01M | 65.62% |
| 2000-12-31 | $24.76M | 135.80% |
| 1999-12-31 | $10.50M | 362.15% |
| 1998-12-31 | $2.27M | - |
Exelixis generated $1.83B in revenue during NA 2023, up 13.60% compared to the previous quarter, and up 214.35% compared to the same period a year ago.
Exelixis Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-28 | $637.18M | 49.84% |
| 2024-03-29 | $425.23M | -11.35% |
| 2023-12-29 | $479.65M | 1.64% |
| 2023-09-29 | $471.92M | 0.44% |
| 2023-06-30 | $469.85M | 14.94% |
| 2023-03-31 | $408.79M | -3.57% |
| 2022-12-30 | $423.92M | 2.96% |
| 2022-09-30 | $411.74M | -1.83% |
| 2022-07-01 | $419.43M | 17.82% |
| 2022-04-01 | $355.98M | -21.09% |
| 2021-12-31 | $451.14M | 37.37% |
| 2021-10-01 | $328.42M | -14.73% |
| 2021-07-02 | $385.18M | 42.54% |
| 2021-04-02 | $270.23M | 0.07% |
| 2021-01-01 | $270.05M | 16.86% |
| 2020-10-02 | $231.09M | -10.94% |
| 2020-07-03 | $259.48M | 14.35% |
| 2020-04-03 | $226.91M | -5.57% |
| 2020-01-03 | $240.31M | -11.55% |
| 2019-09-27 | $271.70M | 13.08% |
| 2019-06-28 | $240.28M | 11.50% |
| 2019-03-29 | $215.49M | -5.74% |
| 2018-12-28 | $228.60M | 1.42% |
| 2018-09-28 | $225.40M | 21.11% |
| 2018-06-29 | $186.11M | -12.36% |
| 2018-03-30 | $212.35M | 76.85% |
| 2017-12-29 | $120.07M | -21.27% |
| 2017-09-29 | $152.51M | 54.04% |
| 2017-06-30 | $99.01M | 22.40% |
| 2017-03-31 | $80.89M | 4.26% |
| 2016-12-30 | $77.58M | 24.74% |
| 2016-09-30 | $62.19M | 71.56% |
| 2016-07-01 | $36.25M | 134.99% |
| 2016-04-01 | $15.43M | 55.23% |
| 2015-12-31 | $9.94M | 0.85% |
| 2015-09-30 | $9.85M | 23.30% |
| 2015-06-30 | $7.99M | -14.87% |
| 2015-03-31 | $9.39M | 27.68% |
| 2014-12-31 | $7.35M | 16.88% |
| 2014-09-30 | $6.29M | -4.13% |
| 2014-06-30 | $6.56M | 33.78% |
| 2014-03-31 | $4.91M | 12.84% |
| 2013-12-31 | $4.35M | -20.47% |
| 2013-09-30 | $5.47M | -53.90% |
| 2013-06-30 | $11.86M | 22.62% |
| 2013-03-31 | $9.67M | 23.74% |
| 2012-12-31 | $7.81M | -41.31% |
| 2012-09-30 | $13.31M | 70.40% |
| 2012-06-30 | $7.81M | -57.79% |
| 2012-03-31 | $18.51M | -80.16% |
| 2011-12-31 | $93.31M | -27.26% |
| 2011-09-30 | $128.27M | 298.83% |
| 2011-06-30 | $32.16M | -10.39% |
| 2011-03-31 | $35.89M | -11.98% |
| 2010-12-31 | $40.78M | -25.15% |
| 2010-09-30 | $54.47M | 14.45% |
| 2010-06-30 | $47.60M | 12.79% |
| 2010-03-31 | $42.20M | -4.26% |
| 2009-12-31 | $44.08M | -19.82% |
| 2009-09-30 | $54.98M | 100.63% |
| 2009-06-30 | $27.40M | 8.30% |
| 2009-03-31 | $25.30M | -14.44% |
| 2009-01-02 | $29.57M | -1.20% |
| 2008-09-26 | $29.93M | -1.58% |
| 2008-06-27 | $30.41M | 8.83% |
| 2008-03-28 | $27.94M | - |
Exelixis generated $637.18M in revenue during Q2 2024, up 49.84% compared to the previous quarter, and up 155.87% compared to the same period a year ago.
Exelixis Revenue Breakdown
Exelixis Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Jan 21 | Jan 20 |
|---|---|---|---|---|---|
| License | $178.63M | - | - | - | - |
| Product, Gross | $2.27B | $1.95B | $1.45B | $962.59M | $957.62M |
| Product, Sales Discounts And Allowances | $-643.65M | $-549.93M | $-375.66M | $-221.04M | $-197.67M |
| Service | $22.69M | - | - | - | - |
| Product | $1.63B | $1.40B | $1.08B | $741.55M | $759.95M |
| Collaboration | $201.33M | $209.82M | $357.71M | $245.99M | $207.82M |
| Collaboration, Other | - | - | - | - | $-3.44M |
| Cabometyx | - | - | - | - | $733.42M |
| Cometriq | - | - | - | - | $26.53M |
| Collaboration, Research And Development Service | - | - | - | - | $49.97M |
| Collaboration, License | - | - | - | - | $161.30M |
Exelixis's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product, Gross (62.08%), Product (44.50%), Collaboration (5.50%), License (4.88%), Service (0.62%), and Product, Sales Discounts And Allowances (-17.58%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Sep 22 | Jul 22 | Apr 22 | Dec 21 | Oct 21 | Jul 21 | Apr 21 | Jan 21 | Oct 20 | Jul 20 | Apr 20 | Jan 20 | Sep 19 | Jun 19 | Mar 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Service | $2.03M | $19.64M | $3.06M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Collaboration | $46.70M | $50.32M | $45.42M | $60.20M | $45.39M | $45.26M | $72.38M | $45.68M | $148.46M | $65.31M | $100.93M | $43.02M | $45.38M | $79.94M | $35.91M | - | - | - | - | - |
| License | $44.68M | $136.27M | $42.37M | $68.03M | $36.39M | $24.51M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Product | $378.52M | $429.34M | $426.50M | $409.65M | $363.40M | $366.48M | $347.04M | $310.30M | $302.68M | $263.12M | $284.25M | $227.21M | $200.35M | $168.59M | $178.73M | $193.88M | $194.93M | $191.77M | $193.68M | $179.58M |
| Product, Gross | $563.78M | $597.60M | $590.44M | $563.17M | $521.32M | $496.14M | $483.07M | $448.24M | $401.04M | $357.46M | $380.20M | $314.20M | $253.54M | $239.92M | $240.42M | $223.75M | - | - | - | - |
| Product, Sales Discounts And Allowances | $-185.26M | - | $-163.94M | $-153.53M | $-157.92M | $-129.66M | $-136.03M | $-137.94M | $-98.36M | $-94.34M | $-95.96M | $-86.99M | - | - | - | - | - | - | - | - |
| Cabometyx | - | - | - | - | - | - | - | - | - | - | - | - | $196.31M | $159.56M | $173.61M | $189.22M | $181.11M | - | - | - |
| Cometriq | - | - | - | - | - | - | - | - | - | - | - | - | $4.05M | $9.03M | $5.12M | $4.66M | $13.82M | - | - | - |
| Research and Development | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $12.99M | $10.90M | $11.93M |
| Other Collaboration | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-1.09M | $-691.00K | $-531.00K |
| Sales Discounts And Allowances | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $48.15M | $46.74M | $44.17M |
Exelixis's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Product, Gross (66.29%), Product (44.51%), Collaboration (5.49%), License (5.25%), Service (0.24%), and Product, Sales Discounts And Allowances (-21.78%).
Exelixis Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Jan 21 | Jan 20 |
|---|---|---|---|---|---|
| UNITED STATES | $1.65B | $1.41B | $1.09B | $752.89M | $770.24M |
| Europe | $144.97M | $168.59M | $302.07M | $151.63M | $152.77M |
| JAPAN | $39.49M | $28.73M | $43.50M | $83.02M | $44.76M |
Exelixis's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (89.92%), Europe (7.92%), and JAPAN (2.16%).
Quarterly Revenue by Country
| Country | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Sep 22 | Jul 22 | Apr 22 | Dec 21 | Oct 21 | Jul 21 | Apr 21 | Jan 21 | Oct 20 | Jul 20 | Apr 20 | Jan 20 | Sep 19 | Jun 19 | Mar 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| JAPAN | $7.59M | $8.31M | $6.29M | $17.07M | $7.81M | $7.44M | $7.57M | $7.39M | $6.08M | $23.89M | $7.07M | $6.47M | $32.87M | $23.53M | $25.33M | $1.28M | $10.39M | $1.20M | $21.68M | - |
| Europe | $35.70M | $38.68M | $36.02M | $36.73M | $33.53M | $34.82M | $62.24M | $34.53M | $139.25M | $38.09M | $90.92M | $33.81M | $33.67M | $36.01M | $52.92M | $29.04M | $32.64M | $76.02M | $22.25M | $21.87M |
| UNITED STATES | $381.94M | $432.66M | $429.61M | $416.04M | $367.44M | $369.48M | $349.62M | $314.06M | $305.81M | $266.44M | $287.19M | $229.96M | $203.51M | $171.55M | $181.23M | $196.60M | $197.29M | $194.48M | $196.35M | $182.13M |
| Other Geographical Areas | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $11.49M |
Exelixis's latest quarterly revenue breakdown by geography, as of Mar 24: UNITED STATES (89.82%), Europe (8.40%), and JAPAN (1.78%).
Exelixis Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| BMRN | BioMarin Pharmaceutical | $2.42B | $712.03M |
| EXEL | Exelixis | $1.83B | $637.18M |
| ALNY | Alnylam Pharmaceuticals | $1.83B | $659.83M |
| SRPT | Sarepta Therapeutics | $1.24B | $413.46M |
| PTCT | PTC Therapeutics | $937.82M | $186.70M |
| HALO | Halozyme Therapeutics | $829.25M | $231.35M |
| TGTX | TG Therapeutics | $233.66M | $73.47M |
| KRYS | Krystal Biotech | $50.70M | $70.28M |
| BTAI | BioXcel Therapeutics | $1.38M | $1.10M |
| XFOR | X4 Pharmaceuticals | - | $563.00K |
| VKTX | Viking Therapeutics | - | - |
| PDSB | PDS Bio | - | - |
| MDGL | Madrigal Pharmaceuticals | - | - |
| KOD | Kodiak Sciences | - | - |
EXEL Revenue FAQ
What is Exelixis’s yearly revenue?
Exelixis's yearly revenue for 2023 was $1.83B, representing an increase of 13.60% compared to 2022. The company's yearly revenue for 2022 was $1.61B, representing an increase of 12.27% compared to 2021. EXEL's yearly revenue for 2021 was $1.43B, representing an increase of 45.31% compared to 2020.
What is Exelixis’s quarterly revenue?
Exelixis's quarterly revenue for Q2 2024 was $637.18M, a 49.84% increase from the previous quarter (Q1 2024), and a 35.61% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $425.23M, a -11.35% decrease from the previous quarter (Q4 2023), and a 4.02% increase year-over-year (Q1 2023). EXEL's quarterly revenue for Q4 2023 was $479.65M, a 1.64% increase from the previous quarter (Q3 2023), and a 13.15% increase year-over-year (Q4 2022).
What is Exelixis’s revenue growth rate?
Exelixis's revenue growth rate for the last 3 years (2021-2023) was 27.54%, and for the last 5 years (2019-2023) was 89.12%.
What are Exelixis’s revenue streams?
Exelixis's revenue streams in c 23 are License, Product, Gross, Product, Sales Discounts And Allowances, Service, Product, and Collaboration. License generated $178.64M in revenue, accounting 4.88% of the company's total revenue Product, Gross generated $2.27B in revenue, accounting 62.08% of the company's total revenue, up 16.47% year-over-year. Product, Sales Discounts And Allowances generated $-644M in revenue, accounting -17.58% of the company's total revenue, up 17.04% year-over-year. Service generated $22.69M in revenue, accounting 0.62% of the company's total revenue Product generated $1.63B in revenue, accounting 44.50% of the company's total revenue, up 16.25% year-over-year. Collaboration generated $201.33M in revenue, accounting 5.50% of the company's total revenue, down -4.05% year-over-year.
What is Exelixis’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Exelixis was Product, Gross. This segment made a revenue of $2.27B, representing 62.08% of the company's total revenue.